vs
景顺（IVR）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
景顺的季度营收约是STANDARD BIOTOOLS INC.的1.1倍（$21.3M vs $19.6M），景顺净利率更高（242.2% vs -177.4%，领先419.6%），景顺同比增速更快（55.4% vs -11.5%），过去两年景顺的营收复合增速更高（74.2% vs -12.2%）
景顺是一家美国独立投资管理公司，总部位于佐治亚州亚特兰大，在全球20个国家设有分支机构。景顺旗下拥有景顺、景顺 perpetual、PowerShares等多个品牌，其普通股纳入标普500指数，在纽约证券交易所挂牌交易。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
IVR vs LAB — 直观对比
营收规模更大
IVR
是对方的1.1倍
$19.6M
营收增速更快
IVR
高出66.9%
-11.5%
净利率更高
IVR
高出419.6%
-177.4%
两年增速更快
IVR
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.3M | $19.6M |
| 净利润 | $51.5M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | — | -168.5% |
| 净利率 | 242.2% | -177.4% |
| 营收同比 | 55.4% | -11.5% |
| 净利润同比 | 1368.7% | -28.8% |
| 每股收益（稀释后） | $0.72 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IVRLAB
| Q4 25 | $21.3M | — | ||
| Q3 25 | $17.6M | $19.6M | ||
| Q2 25 | $17.7M | $21.8M | ||
| Q1 25 | $18.8M | $40.8M | ||
| Q4 24 | $13.7M | — | ||
| Q3 24 | $7.5M | $22.1M | ||
| Q2 24 | $8.6M | $22.5M | ||
| Q1 24 | $7.0M | $45.5M |
净利润IVRLAB
| Q4 25 | $51.5M | — | ||
| Q3 25 | $53.5M | $-34.7M | ||
| Q2 25 | $-23.3M | $-33.5M | ||
| Q1 25 | $19.6M | $-26.0M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $40.7M | $-26.9M | ||
| Q2 24 | $-13.5M | $-45.7M | ||
| Q1 24 | $29.1M | $-32.2M |
毛利率IVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率IVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -120.9% | ||
| Q2 24 | — | -134.5% | ||
| Q1 24 | — | -132.2% |
净利率IVRLAB
| Q4 25 | 242.2% | — | ||
| Q3 25 | 303.6% | -177.4% | ||
| Q2 25 | -131.6% | -153.7% | ||
| Q1 25 | 104.4% | -63.8% | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 542.2% | -122.0% | ||
| Q2 24 | -155.9% | -203.3% | ||
| Q1 24 | 415.9% | -70.6% |
每股收益（稀释后）IVRLAB
| Q4 25 | $0.72 | — | ||
| Q3 25 | $0.74 | $-0.09 | ||
| Q2 25 | $-0.40 | $-0.09 | ||
| Q1 25 | $0.26 | $-0.07 | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $0.63 | $-0.07 | ||
| Q2 24 | $-0.38 | $-0.12 | ||
| Q1 24 | $0.49 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $56.0M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $797.5M | $399.7M |
| 总资产 | $6.5B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IVRLAB
| Q4 25 | $56.0M | — | ||
| Q3 25 | $58.5M | $129.4M | ||
| Q2 25 | $59.4M | $158.6M | ||
| Q1 25 | $42.9M | $150.9M | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $48.3M | $210.6M | ||
| Q2 24 | $58.8M | $269.8M | ||
| Q1 24 | $59.9M | $287.1M |
总债务IVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益IVRLAB
| Q4 25 | $797.5M | — | ||
| Q3 25 | $769.6M | $399.7M | ||
| Q2 25 | $709.4M | $424.5M | ||
| Q1 25 | $759.2M | $454.6M | ||
| Q4 24 | $730.7M | — | ||
| Q3 24 | $857.0M | $489.3M | ||
| Q2 24 | $759.2M | $510.3M | ||
| Q1 24 | $785.6M | $577.3M |
总资产IVRLAB
| Q4 25 | $6.5B | — | ||
| Q3 25 | $6.0B | $539.6M | ||
| Q2 25 | $5.4B | $557.0M | ||
| Q1 25 | $6.2B | $579.6M | ||
| Q4 24 | $5.7B | — | ||
| Q3 24 | $6.1B | $681.5M | ||
| Q2 24 | $5.1B | $708.7M | ||
| Q1 24 | $5.2B | $777.7M |
负债/权益比IVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $157.1M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | 3.05× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流IVRLAB
| Q4 25 | $157.1M | — | ||
| Q3 25 | $37.3M | $-22.2M | ||
| Q2 25 | $40.6M | $-20.7M | ||
| Q1 25 | $19.3M | $-30.3M | ||
| Q4 24 | $183.2M | — | ||
| Q3 24 | $30.8M | $-27.9M | ||
| Q2 24 | $33.0M | $-39.0M | ||
| Q1 24 | $57.5M | $-62.5M |
自由现金流IVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率IVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度IVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率IVRLAB
| Q4 25 | 3.05× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 52.24× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IVR
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
